Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001084101 | SCV000285281 | benign | Tuberous sclerosis 2 | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000564827 | SCV000675650 | likely benign | Hereditary cancer-predisposing syndrome | 2023-07-06 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Eurofins Ntd Llc |
RCV000596298 | SCV000701637 | uncertain significance | not provided | 2016-10-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000596298 | SCV001812618 | likely benign | not provided | 2019-07-24 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001084101 | SCV002039626 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Johns Hopkins Genomics, |
RCV001084101 | SCV003839115 | uncertain significance | Tuberous sclerosis 2 | 2022-12-12 | criteria provided, single submitter | clinical testing | This TSC2 missense variant (rs764725850) is rare (<0.1%) in a large population dataset (gnomAD v2.1.1: 3/251236 total alleles; 0.0012%; no homozygotes). It has been reported in ClinVar (Variation ID 237983), but not in the literature, to our knowledge. Two bioinformatic tools queried predict that this substitution would be tolerated. While the isoleucine residue at this position is evolutionarily conserved across many of the species assessed, several species have a different amino acid at this position, including 4 species with valine. We consider the clinical significance of c.2167A>G; p.Ile723Val in TSC2 to be uncertain at this time. |
Ce |
RCV000596298 | SCV004133831 | likely benign | not provided | 2023-10-01 | criteria provided, single submitter | clinical testing | TSC2: BP4, BS2 |
All of Us Research Program, |
RCV003998811 | SCV004824342 | uncertain significance | Tuberous sclerosis syndrome | 2024-02-05 | criteria provided, single submitter | clinical testing | This missense variant replaces isoleucine with valine at codon 723 of the TSC2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 3/251236 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |